Navigation Links
Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer
Date:7/23/2010

GREAT NECK, N.Y., July 23 /PRNewswire-USNewswire/ -- The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth) to participate in a Phase I clinical trial.

Subjects must be newly diagnosed and not have undergone any previous treatment. Further, their cancer must be unassociated with the human papilloma virus (HPV-negative), or, if it is HPV-positive, they must be current or former pack-a-day smokers for at least 10 years.

Patients with HPV-negative oropharyngeal cancer are not cured as frequently by standard radiation therapy (IMRT) as are patients with the HPV-positive type, according to David Schwartz, MD, vice chair of radiation medicine at the North Shore-LIJ Health System and the study's principal investigator. The hypothesis of the study is that standard radiation therapy followed by a "boost" of image-guided stereotactic radiosurgery (SRS) will achieve a better cure rate for these two groups of patients.

Patients who volunteer to participate in the study are first screened to determine whether they are eligible, after which they provide their informed consent. Treatment can then begin--six weeks of standard radiation, possibly in combination with chemotherapy, depending on the stage of the cancer. Research nurse Sara Parise, RN, BSN, coordinates the patients' treatment.

And now on to the "boost" of SRS, which is what the study is all about. A Phase I trial establishes the safety of a treatment, and so the first group of patients receives a moderate dose of SRS, only 8Gy (Gy stands for gray, a unit of energy absorbed from ionizing radiation). This is a rigorous treatment, comparable to standard doses. All Phase I trials begin with a dose of the experimental treatment that is believed to be safe, followed by very careful monitoring of the patients' reactions. If the dose of 8Gy6 is well tolerated, the next group of patients will get a dose 2Gy higher, and again the side effects will be carefully monitored. The maximum dose will be 18Gy.

"This trial is one of the very first attempts to increase cure rates for the large number of patients with HPV-unassociated oropharyngeal cancer," Dr. Schwartz stated. "SRS is a safe, highly sophisticated technique that has generated much interest for its ability to overcome resistance of tumors to radiation. We are pleased that the North Shore-LIJ Health System has the technology and the expertise to offer this trial before any other center in the metropolitan area or anywhere in the country. Our hope is that it serves as a stepping stone for expanded use of SRS as part of standard treatment for people who face this illness."

To see if you are eligible to participate in the study or to find out more, call Ms. Parise at 718-470-7190, extension 66773.

This news release was issued on behalf of Newswise(TM).  For more information, visit http://www.newswise.com.


'/>"/>
SOURCE North Shore-Long Island Jewish Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
2. Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
3. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
4. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
5. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
6. Worlds Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
7. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
8. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
9. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
10. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
11. Drug Study Shows Improvement in Major Orthopedic Surgery Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016  Cepheid (Nasdaq: CPHD ) today ... Vice President and Chief Operating Officer, has been ... Operating Officer.  In his new capacity, Mr. Kocmond,s ... Commercial Operations in addition to Manufacturing Operations, Engineering, ... continue to report to John Bishop , ...
(Date:2/10/2016)... --> --> This press release is intended for ... Japan .  --> A separate press release has been prepared ... Shire continues to strengthen its presence in ... continues to strengthen its presence in Japan ... continues to strengthen its presence in Japan ...
(Date:2/10/2016)...  Resolve Therapeutics, LLC, a clinical stage biopharmaceutical ... treatment of lupus and Sjogrens syndrome, today announced ... study in patients with systemic lupus erythematosus (SLE) ... --> --> Data from a ... of RSLV-132 in 32 subjects with SLE demonstrate ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club at Ibis ... prestigious Distinguished Emerald Club of the World award, as determined by the annual ... the most respected trade publications serving private clubs. , “We’d like to congratulate ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... – 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional ... Elite Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of ... in the state still face a lot of restrictions as to where they can ... for private, personal use” and that cannabis “may not be consumed openly or publicly.” ...
(Date:2/10/2016)... ... February 09, 2016 , ... Western University of Health Sciences’ ... to 150 children in kindergarten through third grade at Hurley Elementary School in ... Chinese American Dental Society of Southern California volunteers for Give Kids A Smile, ...
Breaking Medicine News(10 mins):